Table 2

Biochemical parameters

Clozapine (n=100)Non-clozapine (n=21)Controls (n=20)p Value (ANCOVA)
Biochemical parameters
 Haemoglobin (g/L)142±15146±13148±100.18
 White cell count (×109/L)8.2±2.67.4±2.46.5±1.50.17
 Neutrophil count (×109/L)5.4±2.24.3±1.83.6±1.00.02*†
  Neutrophil count <2.0×109/L2 (2)3 (14)00.02
  Neutrophil count >7.0×109/L20 (20)2 (10)00.03
 Neutrophil : lymphocyte ratio2.9±1.71.9±1.01.7±0.80.01*
 Eosinophil count (×109/L)0.12±0.10.23±0.10.17±0.10.006†
 Fasting lipids (mmol/L)
  Total cholesterol5.2±1.15.3±1.04.9±0.70.24
   Total cholesterol >5.2 mmol/L40 (40)11 (52)4 (20)0.12
   Statin therapy18 (18)4 (19)00.96
  Triglycerides2.1±1.31.7±0.71.2±0.60.007*
  Total triglyceride >2.0 mmol/L25 (25)3 (15)1 (5)0.41
  HDL-C1.2±0.31.1±0.41.4±0.30.05
  LDL-C3.0±0.93.3±0.83.0±0.70.06
 HsCRP (mg/L)4.3±4.33.4±5.40.9±0.80.05
 NT-proBNP (pmol/L)3.4±4.26.4±9.52.8±2.20.05
 HsTropT (ng/L)9.1±3.26.9±4.45.0±0.00.002‡†
 Creatine kinase (U/L)145±129167±253129±520.36
  Creatine kinase >250 U/L14 (14)4 (19)2 (10)0.91
 HbA1c (%)5.9±1.06.0±1.05.6±0.90.39
  • Values are presented as mean±SD or absolute number (%).

  • ANCOVA with the following covariates in the modelling: age, alcohol excess, BMI, diabetes, gender, history of CCF, history of ischaemic heart disease, hypercholesterolaemia and smoking.

  • *Post hoc Tukey analysis with Bonferroni correction between clozapine and healthy controls, p value <0.05.

  • †Post hoc Tukey analysis with Bonferroni correction between patients receiving clozapine and non-clozapine patients, p value <0.05.

  • ‡Post hoc Tukey analysis with Bonferroni correction between non-clozapine and healthy controls, p value <0.05.

  • ANCOVA, analysis of covariance; BMI, body mass index; CCF, congestive cardiac failure; HbA1c, glycosylated haemoglobin; HDL-C, high-density lipoprotein cholesterol; HsCRP, high-sensitivity C reactive protein; HsTropT, high-sensitivity Troponin T; LDL-C, low-density lipoprotein cholesterol; NT-proBNP, N-terminal pro-B-type natriuretic peptide.